Starfruit has 2 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Nirogacestat, Rilzabrutinib. Patients taking Starfruit should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 2
- Major
- 1
- Moderate
- 1
Major (1)
- Starfruit + Nirogacestat— Strong CYP3A inhibitor. Increases nirogacestat exposure, which may increase risk of adverse reactions.
Moderate (1)
- Starfruit + Rilzabrutinib— Starfruit is a moderate CYP3A inhibitor. Concomitant use increases rilzabrutinib exposure and risk of adverse reactions.